WHO launches “One life, one liver” campaign on World Hepatitis Day

Amalendu Upadhyaya
Posted By -

New Delhi/ Geneva, 28 July: On World Hepatitis Day, the World Health Organization (WHO) launched the “One life, one liver” campaign, urging the expansion of testing and treatment for viral hepatitis. The WHO warned that if current infection trends continue, hepatitis could surpass malaria, tuberculosis, and HIV combined in fatalities by 2040.

Hepatitis is responsible for over a million deaths annually, with hepatitis B and C causing the majority of cases. While hepatitis C is curable, only a small fraction of infected individuals receive proper diagnosis and treatment. Likewise, a mere 10% of those with chronic hepatitis B are diagnosed, and only 2% receive life-saving medication.

To mark World Hepatitis Day, WHO called for scaling up testing and treatment for viral hepatitis, warning that the disease could kill more people than malaria, tuberculosis, and HIV combined by 2040, if current infection trends continue.

Hepatitis causes liver damage and cancer and kills over a million people annually. Of the 5 types of hepatitis infections, hepatitis B and C cause most of the disease and deaths. Hepatitis C can be cured; however, only 21% of people living with hepatitis C infection are diagnosed and only 13% have received curative treatment. Just 10% of people living with chronic hepatitis B are diagnosed, and only 2% of those infected are receiving the lifesaving medicine.

World Hepatitis Day 2023 theme

Under the theme of “One life, one liver”, WHO’s World Hepatitis Day campaign highlights the importance of protecting the liver against hepatitis for living a long, healthy life. Good liver health also benefits other vital organs – including the heart, brain and kidneys – that rely on the liver to function.

“Millions of people are living with undiagnosed and untreated hepatitis worldwide, even though we have better tools than ever to prevent, diagnose and treat it,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “WHO remains committed to supporting countries to expand the use of those tools, including increasingly cost-effective curative medication, to save lives and end hepatitis.”

WHO will share new guidance to track countries’ progress on the path to the elimination of hepatitis by 2030. To reduce new infections and deaths from hepatitis B and C, countries must: ensure access to treatment for all pregnant women living with hepatitis B, provide hepatitis B vaccines for their babies at birth, diagnose 90% of people living with hepatitis B and/or hepatitis C, and provide treatment to 80% of all people diagnosed with hepatitis. They must also act to ensure optimal blood transfusion, safe injections and harm reduction.

Vaccination, testing and treatment – vital opportunities to protect your liver from hepatitis

The reduction of hepatitis B infections in children through vaccination is a key intervention to limit viral hepatitis infections overall. The target for hepatitis B incidence is the only Sustainable Development Goals’ (SDG) health target that was met in 2020 and is on track for 2030. However, many countries in Africa do not have access to birth-dose hepatitis B vaccines. Gavi’s recent restart of its Vaccine Investment Strategy 2018 – which includes the birth dose hepatitis B vaccine – will jumpstart newborn vaccination programmes in West and central Africa, where mother-to-child hepatitis B transmission rates remain very high.

To help eliminate mother-to-child transmission, the WHO recommended that all pregnant women should be tested for hepatitis B during their pregnancy. If positive, they should receive treatment and vaccines should be provided to their newborns. However, a new WHO report shows that of the 64 countries with a policy, only 32 countries reported implementing activities to screen for and manage hepatitis B in antenatal clinics.

The report also shows that of the 103 countries that reported, 80% have policies to screen and manage hepatitis B in HIV clinics, with 65% doing the same for hepatitis C. Increasing hepatitis testing and treatment within HIV programmes will protect people living with HIV from developing liver cirrhosis and liver cancer.

After years of increasing treatment rates, the rise in the number of people accessing hepatitis C curative treatment is slowing. WHO advocates for taking advantage of price reductions in medication to reaccelerate progress in expanding treatment. A 12-week course of medication to cure hepatitis C now costs 60 US dollars for low-income countries, down from the original costs of more than 90 000 US dollars when first introduced in high-income countries. Treatment for hepatitis B costs less than 30 US dollars per year ($2.4 US dollars per month).

For people who want to maintain liver health, WHO recommends hepatitis testing, treatment if diagnosed, and vaccination against hepatitis B. Reducing alcohol consumption, achieving a healthy weight, and managing diabetes or hypertension also benefit liver health.

Post a Comment


Post a Comment (0)